Soticlestat

CAS : 1429505-03-2

Ref. 3D-EHC50503

Informations sur le produit

• Nom: Soticlestat
• Marque: Biosynth
• Description: Soticlestat is an investigational pharmaceutical compound that functions as a selective inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H). This enzyme is predominantly found in the brain, where it catalyzes the conversion of cholesterol to 24S-hydroxycholesterol, a process implicated in neuroinflammation and excitotoxicity. By inhibiting CH24H, Soticlestat aims to reduce the overproduction of 24S-hydroxycholesterol, which is associated with various neurological disorders.The primary source of Soticlestat is synthetic chemical development, characterized by the precision in targeting specific enzymatic processes within the central nervous system. The compound's mode of action involves binding to CH24H, leading to decreased activity of this enzyme and thus reducing downstream neurotoxic effects that can exacerbate conditions such as epilepsy and developmental epileptic encephalopathies.Soticlestat is currently being investigated for its potential therapeutic applications in managing treatment-resistant epilepsy and certain rare pediatric epileptic conditions. By modulating cholesterol metabolism in the brain, it holds the promise of offering new insights and approaches for mitigating neurological dysfunction, ultimately aiming to provide better outcomes for patients with limited treatment options.

Propriétés chimiques

• Masse moléculaire: 373.4 g/mol
• Formule: C₂₃H₂₃N₃O₂
• Degré de pureté: Min. 95%